Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
|Articles|September 16, 2008
- September15 2004
- Volume 11
- Issue 17
The Doctor Will See You, Now
Advertisement
2004 Physician Compensation
and Production Survey
"It's not what you make, but what you keep that makes you successful," goes the old saying. Still, you've go to make it, to start with. According to the American Medical Group Association (www.amga.org) , the following are the median annual gross charges for various medial practice specialties:
Articles in this issue
about 18 years ago
A Doctor's Money Magazine: The Journey Continuesabout 18 years ago
Physician Compensation: Same Story, Different Dayabout 18 years ago
Enjoy the Family Vacation of a Lifetimeabout 18 years ago
How's Your Marriage, Doctor?about 18 years ago
Drive Smart with a Premium Small Carabout 18 years ago
Cinema Consults: SECRET WINDOWabout 18 years ago
Solve the Ambiguous Pension Plan Puzzleabout 18 years ago
Uncover Hidden Costs of Financial Adviceabout 18 years ago
Educate Your College Kids in Financeabout 18 years ago
Dodge Costly Estate Planning MistakesAdvertisement
Related to this article
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy
3
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
4
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
5